Long-Term Clinical and Economic Impact of Automated Insulin Delivery Systems Use in Pediatric and Adolescents Type 1 Diabetes: Results Across Australia, Canada, the United Kingdom (UK), and the United States (USA)
Authors' conclusion
AID therapy was predicted to reduce mid- and long-term diabetes-related complications and improve quality of life while concomitantly reducing the economic burden on health care systems. AID was projected to be cost-effective versus MDI+CGM for pediatrics and adolescents with T1D in all analyzed countries.
Study context
- Population
- Children and adolescents with T1D in Australia, Canada, the UK and the USA; input data from National Health System (NHS) England real-world Automated Insulin Delivery (AID) pilot (prospective follow-up showing 0.63% HbA1c reduction after first year)source study cohort
- Participants
- 251 children
- Comparison
- AID systems vs MDI+CGM
- Outcome
- Cost-effectiveness (ICER per QALY gained)
- Follow-up
- 55-year time horizon
Methodological detailsIQVIA Core Diabetes Model, 55-year time horizon, health care system perspective, country-specific discount rates and direct costs
- IQVIA Core Diabetes Model
- 55-year time horizon
- Health care system perspective
- Country-specific discount rates and direct costs
Main finding
As reported in the abstract
ICER per QALY gained (USD), AID vs MDI+CGM
ICER, Australia
14,590
ICER, Canada
25,798
ICER, UK
32,459
ICER, USA
35,648
Further findings
QALY gains with AID
- QALY gains across all countries
- 1.35 to 2.72
Relative risk reduction for long-term complications with AID
- Proliferative diabetic retinopathy
- 51.3%
- End-stage renal disease
- 39.5%
- Severe vision loss
- 38.8%
Total cost savings with AID
USD
- Australia
- −9340
- Canada
- −28,798
- Range from Australia to Canada
Original publication
Long-Term Clinical and Economic Impact of Automated Insulin Delivery Systems Use in Pediatric and Adolescents Type 1 Diabetes: Results Across Australia, Canada, the UK, and the USA. Diabetes Technol Ther. Published 10 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →